CytRx completes
HIV vaccine trial

CytRx Corp. has announced that an early-stage study of an HIV vaccine candidate has yielded positive results. Researchers at the University of Massachusetts Medical School and Advanced BioScience Laboratories developed the compound, DP6-001, which is based on DNA technology. The trial, which began in April 2004, showed the vaccine to be well-tolerated and effective at producing an immune response to HIV. The trial's 34 healthy volunteers were divided into groups according to how the compound was administered. Each group experienced positive results, whether the vaccine was administered three times a day under the skin or in muscle. Additional human trials are planned. (AP)